ALK-ABELLÓ A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155.2 DKK | +0.45% |
|
+1.24% | +53.36% |
| May. 03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 | |
| May. 02 | ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechAnders Hedegaard (Executives)Welcome all of you. Welcome to all of you who are...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Sector
Pharmaceuticals
Calendar
2024-06-03
- Capital Markets Day
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
155.2
DKK
Average target price
155
DKK
Spread / Average Target
-0.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +53.36% | 4.96B | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- ALK B Stock
- News ALK-Abelló A/S
- Transcript : ALK-Abelló A/S - Shareholder/Analyst Call